BioCentury
ARTICLE | Financial News

Pfizer, JDRF among newco AnTolRx's investors

September 8, 2016 7:00 AM UTC

Diabetes newco AnTolRx Inc. (Cambridge, Mass.) raised $4 million in a series A round led by Pfizer Inc. (NYSE:PFE). Orion Equity Partners and JDRF also participated.

AnTolRx is developing nanoparticles that combine an antigen with tolerogenic molecules to treat immune disorders including Type I diabetes. The particles are designed to induce antigen-specific immune tolerance. In diabetes, the approach aims to prevent immune attacks on pancreatic beta cells, and may eliminate the need for systemic immunosuppression that is required in other approaches, JDRF Director of Strategic Partnerships Michael Batten told BioCentury. ...